Monaco Asset Management SAM Makes New Investment in Nkarta, Inc. $NKTX

Key Points

• Monaco Asset Management SAM acquired 2.37 million Nkarta shares worth approximately $6.7 million, representing about 3.32% of the biotechnology company and 0.5% of the fund’s portfolio.
• Nkarta reported a quarterly loss of $0.54 per share, missing analyst expectations of a $0.36 loss. The stock opened at $2.33, while institutional investors collectively own 80.54% of its shares.
• Analyst sentiment remains mixed but leans positive: the consensus rating is “Moderate Buy” with an average price target of $11.20, although some firms have lowered targets and earnings estimates point to continued losses.

Monaco Asset Management SAM acquired a new stake in shares of Nkarta, Inc. (NASDAQ:NKTX - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 2,373,400 shares of the company's stock, valued at approximately $6,717,000. Nkarta makes up about 0.5% of Monaco Asset Management SAM's portfolio, making the stock its 13th biggest position. Monaco Asset Management SAM owned approximately 3.32% of Nkarta at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. GSK plc purchased a new position in shares of Nkarta in the 4th quarter valued at approximately $5,829,000. Jane Street Group LLC boosted its position in shares of Nkarta by 118.7% during the first quarter. Jane Street Group LLC now owns 134,286 shares of the company's stock valued at $247,000 after purchasing an additional 852,559 shares in the last quarter. Millennium Management LLC purchased a new stake in Nkarta in the third quarter worth $1,549,000. Renaissance Technologies LLC grew its stake in Nkarta by 48.6% in the fourth quarter. Renaissance Technologies LLC now owns 1,702,022 shares of the company's stock worth $3,149,000 after purchasing an additional 556,945 shares during the period. Finally, AQR Capital Management LLC raised its holdings in Nkarta by 300.5% in the first quarter. AQR Capital Management LLC now owns 672,078 shares of the company's stock worth $1,237,000 after purchasing an additional 504,272 shares in the last quarter. Hedge funds and other institutional investors own 80.54% of the company's stock.

Nkarta Stock Performance

NASDAQ:NKTX opened at $2.33 on Monday. Nkarta, Inc. has a 12 month low of $1.70 and a 12 month high of $3.72. The company has a market cap of $166.87 million, a PE ratio of -1.48 and a beta of 0.93. The company has a 50 day simple moving average of $2.64 and a two-hundred day simple moving average of $2.58.

Nkarta (NASDAQ:NKTX - Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.18). Research analysts forecast that Nkarta, Inc. will post -1.54 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. HC Wainwright lowered their price objective on Nkarta to $14.00 and set a "buy" rating for the company in a research report on Tuesday, August 11th. Stifel Nicolaus decreased their price target on shares of Nkarta from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Friday. Weiss Ratings reissued a "sell (d-)" rating on shares of Nkarta in a research report on Wednesday, June 24th. Evercore set a $9.00 price objective on shares of Nkarta in a research note on Monday, May 18th. Finally, Wall Street Zen cut shares of Nkarta from a "sell" rating to a "strong sell" rating in a report on Saturday. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Nkarta has a consensus rating of "Moderate Buy" and an average price target of $11.20.

Key Headlines Impacting Nkarta

Here are the key news stories impacting Nkarta this week:

• Positive Sentiment: Stifel maintains a bullish view: Stifel Nicolaus lowered its price target from $11 to $10 but initiated or reaffirmed a “Buy” rating. The revised target still implies approximately 329% upside from the referenced $2.33 share price, providing a positive catalyst for Nkarta (NKTX). Ticker Report article
• Negative Sentiment: HC Wainwright cut earnings estimates across the forecast period: The firm reduced its EPS forecasts for the third and fourth quarters of 2026 to losses of $0.46 and $0.48, respectively, and lowered its full-year estimates to losses of $1.86 in 2026, $2.26 in 2027, $1.76 in 2028, $1.53 in 2029 and $1.23 in 2030. These revisions indicate expectations for deeper or more persistent losses, which may pressure NKTX despite HC Wainwright retaining its “Buy” rating and $14 price target. MarketBeat analyst estimates article

Nkarta Company Profile

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company's platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta's lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source